Phylogica’s business strategy involves a combination of internal drug discovery and development, early stage partnering and licensing.  Using a multi-faceted strategy allows Phylogica to generate short-term shareholder value through early-stage partnering and licensing, with long term value from developing its own portfolio of Phylomer® drugs.

To learn more about Phylogica’s partnering opportunities – click here.